BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.
Abstract accepted at EHA2023 describing the potential for BTK degradation to overcome identified BTK resistance mutations in comparison to covalent and non-covalent BTK inhibitors.

Chat with BeiGene